Michael Chen
Dr. Chen Chen (Michael) currently works as Head of External Innovation China and APAC for Merck KGaA. Michael leads collaborations with academic institutions and local pharmaceutical companies in China and APAC areas with alignment of Merck R&D focus and requirement. He encompasses scouting and evaluation of external opportunities including assets from discovery to clinical development stages, new drug target/biomarker findings, and novel discovery technologies, through open innovation, licensing, co-development, investment and other collaboration models. He also provides his duties within Merck global BD team for various internalization and externalization opportunities.
Michael received his bachelor’s degree in cell and molecular biology from University of Essex, a master degree in cancer immunotherapy from University of Nottingham and a PhD in Biochemistry from Imperial College London. Before joining Merck, he has been leading research projects at Spirogen Ltd./MedImmune, and involved in business development/investment activities at WuXi AppTec and ChemPartner.
陈博士担任默克雪兰诺医药研发外部创新中国/亚太区负责人。工作内容与默克研发战略需求一致，通过与卓越的学术研究中心，以及中国和亚太地区制药公司的合作，来推动新的业务机会。他通过开放创新、引进许可、合作开发、投资和其他合作方式探索评估业务机会，内容包括：研发或者临床开发阶段的项目、新药靶标发现、新兴生物药技术等等。他同时还负责默克商务拓展部门的相关工作，开展各种内外部合作业务。
陈博士先后获得埃塞克斯大学获得细胞和分子生物学学士学位、诺丁汉大学获得癌症免疫治疗硕士学位、伦敦帝国学院获得生物化学博士学位。在加入默克之前，他一直在生物技术公司Spirogen以及阿斯利康旗下全球生物制药分公司MedImmune领导研究项目，并参与和无锡药名康德和睿智化学业务开发及投资活动。
Ying Luo
Nick Lench
Nolan Townsend
Richard West
Josie Elias
Debra Bass
